Ed Jarbath has more than 22 years of biopharmaceutical experience. He serves as president of ScioScientific, LLC, a strategic medical communications firm, where he advises and supports clients such as Bayer, Pfizer, Exelixis, Acceleron Pharma, Lexicon Pharmaceuticals, Sun Pharmaceuticals, Takeda Pharmaceuticals, and many other leading biopharmaceutical firms.
Previously, Jarbath worked for GlaxoSmithKline and Pfizer in sales, sales management, mergers and acquisitions, and marketing management at increasing levels of responsibility, both domestically and internationally, in therapeutic categories such as oncology, virology, and rheumatology. Of note, during his tenure at Pfizer, he was a principal leader of the US $1.1 billion European launch of Celebrex across 27 markets in 18 months.
Prior to working in the biopharmaceutical industry, Jarbath was a fixed income securities analyst (medium
Jarbath has provided leadership in the community as a past vice president of the Board of Directors of CancerCare — a leading patient advocacy and charity organization — where he received the Ben Yedlin Award for Leadership.
Jarbath holds a B.A. in economics (N.Y. State Regents Academic Excellence Scholar) from Binghamton University, an MBA in Finance (with honors) from The McColl School of Business at Queens University of Charlotte, and an M.S. in the Management of Technology (Moore Scholar) from a co-sponsored program of The Wharton School and the School of Engineering and Applied Science of the University of Pennsylvania.